2021 IPO

Humacyte Stock

Regenerative Medical Technology Company

Sign up today and learn more about Humacyte Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2004

Notable Investors

California Institute for Regenerative Medicine

Headquarters

Morrisville NC, US

Total Funding

$436M

About Humacyte Stock

Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products called human acellular vessels (HAV) for regenerative medicine and vascular surgery applications. The company was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Investors

California Institute for Regenerative Medicine

Humacyte

Bangkok bank

Humacyte, R3

Pacific Eagle Asset Management

Humacyte

Funding History

January 2015$74.1M
October 2015$136M
March 2018$75.0M
June 2018$150M

Management

Chief Executive Officer

Jeffrey Lawson

Chief Financial Officer

Douglas Blankenship

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo